In this study the potential of using Leishmania donovani gamma-glutamylcysteine synthetase (glutamate-cysteine ligase, gamma-GCS) as a rational target for vaccine development was determined. Mice, immunised with plasmid containing the full gene sequence for gamma-GCS (pVAX-gamma GCS) or plasmid alone (pVAX control), were challenged with a high dose of L. donovani amastigotes to give a stringent test of the ability of the vaccine to protect against infection. Vaccination with pVAX-gamma GCS resulted in the production of specific IgG1 and IgG2a antibodies and resulted in significantly lower liver parasite burdens compared to controls. Protection was also associated with a significant increase in cell-mediated immunity, demonstrated as an increase in nitrite production by ConA stimulated splenocytes, an increase in the percentage of splenic CD3(+)CD4(+) cells, and enhanced granuloma maturation, compared to control values. (C) 2007 Elsevier Ltd. All rights reserved.
- leishmania donovani
- gamma-glutamylcysteine synthetase
- experimental visceral leishmaniasis
- sodium stibogluguconate
- BALB/C MICE
- murine leishmaniasis
- major infection